Santen Oy
🇫🇮Finland
Clinical Trials
41
Active:32
Completed:9
Trial Phases
2 Phases
Phase 1:13
Phase 3:6
Drug Approvals
7
EMA:5
NMPA:2
Drug Approvals
Tafluprost and Timolol Maleate Eye Drops
- Product Name
- 他氟噻吗滴眼液
- Approval Number
- 国药准字HJ20250033
- Approval Date
- Mar 25, 2025
NMPA
Ciclosporin Eye Drops （III）
- Product Name
- 环孢素滴眼液(Ⅲ)
- Approval Number
- 国药准字HJ20220043
- Approval Date
- Apr 29, 2022
NMPA
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
Phase 1
13 (68.4%)Phase 3
6 (31.6%)A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension
Phase 1
Completed
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- Drug: Preservative free tafluprost opthalmic solution
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2017-10-10
- Lead Sponsor
- Santen Oy
- Target Recruit Count
- 17
- Registration Number
- NCT02102750
- Locations
- 🇺🇸
Childrens Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
🇬🇧Moorfields Eye Hospital, London, United Kingdom
Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Preservative free tafluprost 0.0015% eye dropsDrug: Preservative free timolol 0.5% eye dropsDrug: Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops
- First Posted Date
- 2011-09-15
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Santen Oy
- Target Recruit Count
- 15
- Registration Number
- NCT01434888
- Locations
- 🇫🇮
Kuopio University Hospital Eye Clinic, Kuopio, Finland
Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations
Phase 3
Completed
- Conditions
- Ocular HypertensionOpen-angle Glaucoma
- Interventions
- Drug: Fixed Dose Combination of tafluprost and timolol
- First Posted Date
- 2011-03-01
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Santen Oy
- Target Recruit Count
- 401
- Registration Number
- NCT01306461
Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies
Phase 3
Completed
- Conditions
- Ocular HypertensionOpen-angle Glaucoma
- Interventions
- Drug: Timolol/ FDC/ Placebo/ Tafluprost
- First Posted Date
- 2011-02-09
- Last Posted Date
- 2013-03-13
- Lead Sponsor
- Santen Oy
- Target Recruit Count
- 600
- Registration Number
- NCT01292460
- Locations
- 🇫🇮
Eye clinic, University Hospital of Kuopio, Kuopio, Finland
🇫🇮Eye Clinic, University Hospital of Oulu, Oulu, Finland
Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops
- First Posted Date
- 2010-03-16
- Last Posted Date
- 2013-05-31
- Lead Sponsor
- Santen Oy
- Target Recruit Count
- 185
- Registration Number
- NCT01087671
- Prev
- 1
- 2
- Next
News
No news found